FilingSEC EDGAR6-K
The9 Investee Nanyang Biologics Advances Toward Nasdaq Listing
· SEC accepted
StageIn progress
Filing content
The9's investee, Nanyang Biologics, is advancing toward a Nasdaq listing following shareholder approval of its business combination. The9 expects to hold approximately 15% to 16% of the combined company.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…